This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in

1. CALL
NOW FOR
EARLY BIRD
Cell Based
DISCOUNTS
Assays Americas
Market prospects for more cost-effective drug discovery, development
and toxicity testing using advances in methodology
July 19th - 20th, 2012, The Seaport Hotel, Boston, USA BOOK NOW!
Key Speakers
Sashi Nadanaciva, Principal Scientist, Pfizer R&D
Douglas Auld, Sr. Research Investigator I, Novartis
Arijit Chakravarty, Senior Scientist, Millennium Pharmaceuticals
Regis Doyonnas, Senior Principle Scientist, Pfizer
Okechukwu Ukairo, Sr. Principal Scientist, Hepregen Corporation
Robert Graves, Senior Scientist, GE Healthcare
Marcie Glicksman, Director Lab for Drug Discovery, Harvard NeuroDiscovery Center
Deborah Moshinsky, Founder and President, Cell Assay Innovations
Jim Beltzer, Senior Cell Processing Specialist, Terumo BCT Robert Graves, Senior Scientist, GE Healthcare
Tetsuro Wakatsuki, Co-Founder & Chief Scientific Officer, InvivoSciences
Grace Wong, CEO, ActoKine Therapeutics
Mehmet Fatih Yanik, Assoc. Professor, MIT
Shantanu Singh, Research Fellow, Imaging Platform, Broad Institute of Harvard and MIT
Grant Cameron, RAFT Development Director, TAP Biosystems
Thorsten Gorba, Director, CNS Assay Screening and Development, StemCells, Inc.
Peter Sartipy, Senior Principal Scientist, Department Head, Cellectis Stem Cells
Silver Sponsor Exhibitors matrical
bioscience
Driving the Industry Forward | www.futurepharmaus.com
Media Partners Organised By
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/CellBasedAssaysUSA

2. Conference Introduction
Cell Based Assays Americas
July 19th - 20th, 2012, Boston, USA
Dear Colleague,
Drugs recalls due to toxicity not only have a huge effect on the cost of Who should attend this conference?
developing new therapeutics but it also leads to many years of wasted
research. That is why it is vital to get things right from the outset with more Presidents, Chief Executives, Chief Scientific Officers, Chief
precise testing of new leads using more accurate in-vitro models. High
Throughput Screening using biochemical assays has been a mainstay of the Operating Officers, Senior Vice Presidents, Vice Presidents,
pharmaceutical industry in the past, but with the cost of developing a single
Heads, Senior Directors, Directors, Clinicians, Principal
lead reaching exorbitant amounts, it is now necessary to look at more cost-
efficient methods that more accurately represent the in-vivo environment. Scientists, Principal Investigators, Managers, Project/Team
cell based assay platform has now been integrated into the HTS
The Leaders in:
pipeline to provide more accurate analyses of new drug leads and their
activity in-vivo. It already makes up 50% of the HTS activity by the top
• Bioanalytical Development
pharmaceutical companies and the industry is set to grow at a rate of
15% CAGR by 20151. In addition to being a more accurate platform for
• High-Throughput/High-Content Screening Operations
developing drugs, it also reduces costs incurred by toxicology testing in
animals and mitigates the risk of future recalls.
• Compound Profiling
Why you should attend this conference:
• Drug Discovery/Validation
• Future growth opportunities in the cell based assays market
• ow to reduce costs in the drug development process and produce more
H • Drug Delivery
accurate results earlier.
• Explore new techniques for lead discovery and target identification • Lead Generation
• iscover advances in core components required for the cell based assay
D
• In Vitro Sciences
platform
• ovel outputs using label-free detection methods that reduce interference
N • ADMET
in cellular signaling
• evelopments in software analysis for the outputs generated by different
D • Pre-clinical Development
cell based assays
• Medicinal Chemistry
• ell culture advances and methodology as the platform moves from 2D
C
to 3D
• Toxicology
• ell procurement using induced pluripotent stem cells to mimic human
C
disease pathology
• Stem Cell Technologies Platforms
• ecreating more accurate models of human disease and their response
R
to new drugs • Pharmacovigilance and Safety Testing
• Advances in process automation and management of data
• Chemistry and Bioapplications
I look forward to meeting you at the conference
Best regards • GPCR/Kinases/Molecular Pharmacology
• External/Contract Research
• Pharmacokinetics/Pharmacodynamics
Shahidul Islam
• Global Research and Development
Conference Producer
• Business Development
• Investment and Venture Capital

3. Day 1
Cell Based Assays Americas
Thursday July 19th, 2012
09:00 Registration and refreshments Gene-induction-assay: A useful approach for screening
14:00
existing drugs for new therapeutic indications in the
09:30 Opening address from the Chair areas of radioprotection anti-viral activity
Grace Wong • dentify AK-1 inducible genes involved in radioprotection and AK-2
I
CEO inducible genes involved in anti-viral activity
ActoKine Therapeutics
• alidate biological properties by gene silencing. Gene-induction-assay
V
approach will be used to screen existing drugs for properties that mimic
09:40 Session to be announced
the actions of AK-1 and AK-2 proteins.
Arijit Chakravarty
Senior Scientist • iscover new therapeutic indications for known drugs in the areas of
D
Millennium Pharmaceuticals radioprotection and prevention of infections by existing or emerging viruses
• xamine combined therapy of AK-1 or AK-2 with known drugs used in
E
10:20 High Content Screening Strategy for the rare
A the immunotherapy of cancer and viral diseases
Neurological disease Amyotrophic Lateral Sclerosis Grace Wong
• aboratory for Drug Discovery for Neurodegeneration (LDDN) is an
L CEO
academic drug discovery center that collaborates with the academic
ActoKine Therapeutics
community to accelerate the identification of novel therapeutics.
• myotrophic Lateral Sclerosis (ALS, Lou Gehrig’s disease) is a rare
A
neurodegenerative disease. There are at least six genes that can cause 14:40 Approaches to interpreting cell-based assay results
ALS. The genetic causes of ALS can provide a number of clues to the
mechanism of the disease as well as good potential therapeutic targets. in chemical biology
• e have done a high throughput high content screening assay to screen
W • nvestigation of new reporter enzymes to improve reporter-gene assay
I
our compound library for modulators of one of the genes targets that is a design and result interpretation
DNA/RNA binding protein, TDP-43 (TAR DNA-binding protein 43).
• se of focus libraries in the characterization of cell-based assays
U
• he stages to develop a high throughput high content assay will be
T
discussed along with the results from the screen. • igh-content approaches
H
Marcie Glicksman Douglas Auld
Director Lab for Drug Discovery Sr. Research Investigator I
Harvard NeuroDiscovery Center
Novartis
11:00 Morning refreshments
15:00 Afternoon Refreshments
11:20 High Content Imaging Assays that identify
Compounds which impair Mitochondrial and 15:20 Microfluidic system for on-chip high-throughput
Lysosomal function
whole-animal sorting and screening at sub-cellular
Sashi Nadanaciva
Principal Scientist resolution
Pfizer RD • creening whole organisms for HCA
S
• pplication to drug discovery and toxicity testing
A
12:00 Developing Reproducible and Scalable Methods to
Mehmet Fatih Yanik
Culture Stem Cells: From the Microwell Plate to the
Assoc. Professor
Bioreactor
MIT
• pproaches to finding the right culture conditions to meet your needs
A
• atrix, media and cell line considerations for optimal growth and
M
performance
16:00 Cellular systems that address the efficacy, selectivity,
• rivers for scale up, manufacturing concerns and potential bottlenecks
D
and mechanism of action of kinase inhibitors
• ags, bioreactors, micro-carriers, hollow fiber and fixed bed bioreactors
B
• Development and validation of a kinase cell-based assay platform
Jim Beltzer
Senior Cell Processing Specialist • tility for drug discovery (HTS, MOA determination, and lead optimization)
U
Terumo BCT
• Utility of the platform for selectivity analysis in cells
• Multiplex screening to improve efficiencies
12:40 Drug Discovery through 3D Engineered Tissue-Based
• Application to HTS for drug resistant mutant multiplexed analysis
Compound Analysis
• irst-in-class drug discovery through engineered tissue-based high
F Deborah Moshinsky
content analysis Founder and President
• ardiotoxicity assessments with human engineered heart tissues
C Cell Assay Innovations
• ulti-stage phenotypic screening for discovering a cardiac fibrosis
M
treatment
• ast Track drug discovery in a skeletal muscle disease treatment
F 16:40 Closing remarks from the Chair
Tetsuro Wakatsuki
Co-Founder Chief Scientific Officer
InvivoSciences 16:50 Networking Drinks
Take your discussions further and build new
13:00 Networking lunch relationships in a relaxed and informal setting
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2012

4. Day 2
Cell Based Assays Americas
Friday July 20th, 2012
09:00 Registration and refreshments 14:20 High-content screening in physiologically relevant
contexts
09:30 Opening address from the chair • o-cultures of stem cells can be screened by microscopy to study
C
Sashi Nadanaciva hematopoiesis and leukemia
Principal Scientist
• o-cultures of hepatocytes can be screened by microscopy to study liver
C
Pfizer RD
functions and hepatotoxicity
• . elegans can be screened by microscopy to study infection and
C
09:40 Development of phenotypic screening platforms for
metabolism in intact animals
the evaluation of putative autophagy enhancers
Regis Doyonnas Shantanu Singh
Senior Principle Scientist Research Fellow, Imaging Platform
Pfizer Broad Institute of Harvard and MIT
10:20 Novel Micropatterened Hepatocyte Co-culture
A
System for Drug Metabolism and Toxicity Studies 15:00 Afternoon refreshments
• eed for clinically-relevant and higher throughput liver models for drug
N
screening
• verview of a microscale hepatocyte co-culture system
O 15:20 Stem cell derived cardiomyocytes in cell based assays
• dvantages of the co-culture system: Relevant examples of how the
A mimicking in vivo tissue-like responses
microscale hepatocyte co-culture system could aid in toxicity prediction
and prediction of human in vivo metabolites • erivation and characteristics of cardiomyocytes from human pluripotent
D
stem cells
Okechukwu Ukairo
Sr. Principal Scientist • pportunities and limitation of current state-of-the-art stem cell derived
O
Hepregen Corporation cardiomyocytes in cell based assays
• ase studies of stem cell derived cardiomyocytes as alternatives to in vivo
C
11:00 Morning refreshments and ex vivo animal models
Peter Sartipy
11:20 novel, rapid and automated method for creating
A Senior Principal Scientist, Department Head
3D tissue models to study complex cell behaviour Cellectis Stem Cells
• What type of information can 3D tissue models provide?
• What is preventing widespread adoption of 3D tissue models?
• The route to scalable and tuneable 3D tissue models 16:00 Panel Discussion: Opportunities and challenges for
Grant Cameron human stem cells in drug screening
RAFT Development Director
TAP Biosystems • o models based on human dervied stem cells accurately reflect in-vivo
D
conditions?
12:00 Session to be announced • hat hurdles remain in the path to replacing animal testing with cellular
W
Robert Graves assays?
Senior Scientist
• thical dilemmas related to embryonic stem cells
E
GE Healthcare
Peter Sartipy, Senior Principal Scientist, Department Head
12:40 Networking lunch Cellectis Stem Cells
Marcie Glicksman, Director Lab for Drug Discovery
13:40 CNS based assays for automated drug discovery and Harvard NeuroDiscovery Center
profiling Thorsten Gorba, Director, CNS Assay Screening and Development,
• tem cell-based integrated platform for in vitro and in vivo screening and
S StemCells, Inc.
toxicity assays using the same human target cells of interest across the
entire continuum from discovery to preclinical testing Grace Wong, CEO, Actokine Therapeutics
• ultiplexed HCA and live cell assays to improve validation of leads
M
• ase studies of optimized protocols for automated human neural stem
C
cell production and of a proliferation screen 16:40 Chair’s closing remarks
Thorsten Gorba
Director, CNS Assay Screening and Development
StemCells, Inc. 16:50 End of Conference
Cell-Based Assays: World Market Prospects 2011-2026
RE
Are you looking for pharmaceutical RD market data - answers to save you time and effort, aiding decisions?
PO
Our new report shows you spending trends and revenue prospects for cell-based assays in pharma.
RT
We give market data for 2009 to 2026.

5. Partners
Cell Based Assays Americas
July 19th - 20th, 2012, Boston, USA
Silver Sponsor
InvivoSciences LLC is a frontier in developing next generation 3D cell culture and assay systems Sponsorship and
to provide unprecedented solutions in biomedical research, cosmetics, and toxicology screening. exhibition opportunities:
Current in vitro studies are confined largely to 2D cell culture models. However, most human cells
have 3D interactions. Application of our products, a high-throughput screening device (Palpator™) This event offers a unique opportunity to
and 3D cell culture systems, can narrow the gap between 2D cell culture studies and in vivo meet and do business with some of the
analysis. Effects of drug candidates, chemicals, and gene products on the physiological properties of key players in the pharmaceutical and
3D cell culture systems, forming reconstituted tissues, that mimic in vivo tissue/organ functions are quantified rapidly biotech industries. If you have a service
and cost-effectively. For further information please visit www.invivosciences.com or product to promote, you can do so at
this event by:
Exhibitors • Hosting a networking drinks
Matrical Bioscience is a leading supplier in the life-science research market through reception
matrical the development of innovative, quality products targeted for drug discovery and
bioscience
genomics applications. All products are cooperatively designed between our engineers • Taking an exhibition space at the
and biochemists/biologists to ensure a reliable cost-effective solution that meets or exceeds our customers’ conference
expectations. Matrical Bioscience is a worldwide supplier of automated storage platforms (MiniStore), automated • Advertising in the delegate
biobanking systems (NitroStore), automated assay platform (AutoMAP), automated cell culture systems documentation pack
(MACCS), high throughput sonication devices (SonicMan), universal microplate washer (SQUIRT), consumable
microwell plates in 96, 384, 1536 formats and tube technology for chemical and biological sample storage. • Providing branded bags, pens, gifts,
For further information please visit www.matrical.com etc.
If you would like more information on
TAP Biosystems provides advanced automation systems and services in 4 key the range of sponsorship or exhibition
application areas: cell-based testing, regenerative medicine, drug discovery and possibilities for visiongain's Cell Based
bioprocessing TAP will be exhibiting and presenting the new RAFT™ 3D cell Assays Americas Conference,
culture system. RAFT can be used as a platform technology to support assay development and secondary screening please contact us.
programs, as well as a broad range of cell biology research applications.
Damian Gorman,
SCIVAX Corporation is a Nano-technology company featuring Nano-imprinting. SCIVAX +44 (0)20 7549 9934
focus on commercialization of the Nano-imprinting application, and one of the products damian.gorman@
is our NanoCulture® Plate for biotechnology application. NanoCulture® Plate is a visiongainglobal.com
READY-TO-USE SBS format microplate, which can form 3D spheroids on the well bottom film with nano-
imprinted micro scaffold, without any matix and troublesome procedures. 3D spheroids can be cultured just
by adding standard cell culture medium to the well, and seeding. 3D spheroids of various cell types cultured
on our NanoCulture® Plate show in vivo like characters compared to monolayer cells, and is being used for About visiongain:
various application such as cancer drug screening, cell based assay, IPS/ES cell culture, etc. V
isiongain is a specialist business
For further information please visit www.scivax.com/usa/ information company focused on
providing cutting edge products and
Media Partners services across the Pharmaceutical/
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Biotech, Telecommunications, Defence
Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides and Finance sectors, which include
dynamic real-time news, features, events listings and international jobs to industry professionals across Europe reports, conferences, online daily news
and the US. and offline news analysis and bespoke
For further information please email: corporate@pharmiweb.com consultancy. With a commitment to
innovation and excellence, visiongain
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located offers flexible solutions to meet our
in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s clients’ business intelligence needs,
biotech and pharma information and market to make it universally accessible and useful for scientific and providing the right information
business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE at the right time to facilitate the
platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers commercial decision-making process.
companies completed internet public relations, publication and marketing solutions. One of the mains goals Our pharmaceutical products include
of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, Pharma Business Daily, the leading
pharmaceutical and life science activities. daily email newsletter for the
For further information please visit www.biotechnology-europe.com pharmaceutical, biotech and healthcare
industries, and a range of independent,
InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, high-quality, in-depth reports covering
services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. focused and topical areas of concern.
For further information please visit: www.In-Pharm.com Our pharmaceutical conferences
address the hottest commercial,
Future Pharmaceuticals has forged powerful relationships with key industry leaders to
Driving the Industry Forward | www.futurepharmaus.com
regulatory and technical topics and
provide a platform for successful brand recognition, and for senior decision-makers to
provide an ideal forum for debate
have the means to procure and plan implementation strategies based on the topics covered. Positioned to
and networking for pharmaceutical
be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future
professionals from around the world.
Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive
audience, bridging the gap between the industries’ top issues and the solutions top-tier vendors can provide. F
or further information, please
For further information please visit: www.futurepharmaus.com visit www.visiongain.com

6. Registration Form
Cell Based Assays Americas
July 19th - 20th, 2012, Boston, USA
For multiple bookings
Cell Based Assays
Photocopy this form Conf. code VG
Americas
Standard Prices July 19th – 20th, 2012
Location: The Seaport Hotel
Conference only Fee: £1299 (USD* 2006) Address:
One Seaport Lane
Boston
MA 02210
USA
*USD price is estimate only
Promotional Literature Distribution
Distribution of your company’s promotional literature to all conference attendees How to book
Fee: £999 VAT:
£199.80 Total:
£1198.80 Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/CellBasedAssaysUSA
Details UK Office:
Tel: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9932
Forename: Surname:
Visiongain Ltd
230 City Road
Job Title: Company: London
EC1V 2QY
UK
Main Switchboard Number:
General information
Address: Venue: The Seaport Hotel, One Seaport Lane, Boston, MA 02210, USA
Front Desk Phone: 001 617.385.4000 | Front Desk Fax: 001 617.385.4001
http://www.seaportboston.com/
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee
Country: Postcode: may be requested if payment has not been received in full before the event. Visiongain Ltd reserves
the right to charge interest on unpaid invoices.
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
Phone: Fax: made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
after one month before the start of the event. Should you decide to cancel after this date, the full invoice
Email: must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
between conferences. However, if you cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email, fax or post. Name changes and
Signature: substitutions must be from the same company or organisation and are not transferable between
countries. Please note that discounted delegates places at a visiongain event are non refundable.
I confirm that I have read and agree to the terms and conditions of booking Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
Methods of payment Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
Payment must be made in sterling due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
By Mail: Complete and return your signed registration form together with your cheque expenses, which may be incurred by the customer as a consequence of the event being postponed or
payable to Visiongain Ltd and send to: visiongain Ltd, 230 City Road, London, EC1V 2QY, UK cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
By Fax: Complete and fax your signed registration form with your credit card details Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Protection Act 1988. Your personal information contained in this form may be used to update you on
to +44 (0) 20 7549 9932
visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details
wish for your details to be amended, suppressed or not passed on to any external third party, please
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932
By EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Please allow approximately 30 days for your removal or update request to be applied to our database.
By Bank Transfer Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Please debit my credit card:
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
Access MasterCard Visa American Express This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
Card number: VAT: VAT will be charged at the local rate on each conference. TaxPort USA Corp. specializes in
recovering cross-border VAT. Delegates may be able to recover VAT incurred by contacting TaxPort
Expiry Date: USA Corp.on: Tel: USA 802.860.0250 or +1.888.298.8296, Europe +41(0)21 310 01 50 or via
email on: vat@taxport-usa.com, vat@taxport-switzerland.com, vat@taxport-uk.com. For further
information please check Terms and Conditions on the visiongin.com web site
Security number (last 3 digits on back of credit card):
How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Signature:
Unable to attend
Cardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
with your payment. You will receive speaker talks in PDFs two weeks after the event.
Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
News updates
Office use only
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/CellBasedAssaysUSA